Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

J&J Announces Promising Data for Darzalex Faspro® (Daratumumab and Hyaluronidase-fihj) and Tecvayli® (Teclistamab-cqyv)

Dec 8, 2024

On 8 December 2024, Johnson & Johnson (J&J) announced data showing that Darzalex Faspro® (daratumumab and hyaluronidase-fihj) )-based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.  The results were demonstrated in an analysis of the Phase 3 CEPHEUS study (NCT03652064) and a post hoc analysis of clinically relevant subgroups in the Phase 3 AURIGA study (NCT03901963).

On the same day, J&J also announced new frontline data featuring Tecvayli® (teclistamab-cqyv) from two investigational studies, MajesTEC-5 (NCT05695508) and MajesTEC-4 (NCT05243797).

In the MajesTEC-5 study, patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) were treated with Tecvayli® in combination with Darzalex Faspro® (daratumumab and hyaluronidase-fihj), lenalidomide and dexamethasone or Darzalex Faspro®, bortezomib, lenalidomide and dexamethasone.  All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10-5) and maintained through cycle 6.

Results from the MajesTEC-4 study demonstrated the potential for Tecvayli® to be administered as a maintenance therapy following autologous stem cell transplant (ASCT).

Earlier this year, the US FDA approved J&J’s supplemental Biologics License Application (sBLA) to use Tecvayli® with a reduced dosing frequency for cancer patients (February 2024).